Culture and Well-being: Art as Prescription Therapy ("Art on Prescription") (AoP)

K

KAVADIA ELENI

Status

Enrolling

Conditions

Emotional Disorder
Schizophrenia
Mental Health Issue
Anxiety Disorders
Autism
Depressive Disorder

Treatments

Other: Arts

Study type

Interventional

Funder types

Other

Identifiers

NCT06361667
1/02.02.2024

Details and patient eligibility

About

Cluster randomised controlled trial with two arms: arts intervention (any of the arts interventions, see list), which we call here Active Group (AG) vs waitlist control (WL).

Full description

Design Cluster randomised controlled trial with two arms: arts intervention (any of the arts interventions, see list), which we call here Active Group (AG) vs waitlist control (WL). Clustering will happen at each site. Invastigators want to measure AG and WL, then WL becomes AG after 3 months and both the initial AG and the WL. AG will be measured in exactly the same way for another 3 months. AG for 3 months. Then goes into 3 month follow up. WL for 3 months. Then this group receives intervention and becomes AG and has measurements for 3 months as the AG did. There will be a 2-month break between T3 and T4 due to summer vacation. In the beginning, an open invitation to institutions of culture and mental health had been sent. Culture institutions i.e. Opera House, Contemporary Art Museum, National Theater etc. presented their action plans for interventional courses. Investigators did the connection between mental health and culture institutions. Potential participants declared their preference for the interventional course such as dance, cinema etc. and they listed while an external investigator did the blind randomization into AG or WL group. Frequency of Measurement: The primary outcome will be measured at time points (for adults): T0: (before the randomisation; patient's personal data and demographics) T1: (before the start of the intervention for the active group or the entry into the study for the WL group) T2: 6 weeks (after the start of the intervention for the active group or the entry into the study for the WL group) T3: 12 weeks (after the start of the intervention for the active group or the entry into the study for the WL group) The secondary outcomes will be measured at time points 0 (T4) and 12 weeks (T5) for both AG and WL. The primary outcome will be measured at time points (for children/adolescents): T0: (before the randomisation; patient's personal data and demographics) T1: (before the start of the intervention for the active group or the entry into the study for the WL group) T3: 12 weeks (after the start of the intervention for the active group or the entry into the study for the WL group) The secondary outcomes will be measured at time points 0 (T4) and 12 weeks (T5) for both AG and WL.

Enrollment

384 estimated patients

Sex

All

Ages

10 to 99 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • age range: 10-99 years
  • be able to communicate effectively in order to provide answers to questionnaires that he/she will be asked to complete
  • be able to commit to monitoring the action
  • be able to participate in the activity alone (unaccompanied, without a carer),
  • be able to answer the questionnaires
  • to have legal capacity

Exclusion criteria

  • active dependency,
  • patients that are not consistent in following pharmaceutical drugs,
  • patients from different Patient Association which is not "affiliated" with a Mental Health Professional Therapist.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

384 participants in 2 patient groups, including a placebo group

Active Group (AG)
Experimental group
Description:
This arm will receive the arts intervention (any of the arts interventions).
Treatment:
Other: Arts
Waitlist Control (WL)
Placebo Comparator group
Description:
This arm will be the waitlist control and after 3 months it will be active.
Treatment:
Other: Arts

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Nikos Stefanis, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems